Welch & Forbes’s Ginkgo Bioworks DNA Stock Holding History

Welch & Forbes’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$297K	Hold	30,000	–	–	﹤0.01%	342
2026 Q1	$184K	Hold	30,000	–	–	﹤0.01%	364
2025 Q4	$249K	Hold	30,000	–	–	﹤0.01%	348
2025 Q3	$437K	Hold	30,000	–	–	0.01%	288
2025 Q2	$338K	Hold	30,000	–	–	﹤0.01%	311
2025 Q1	$171K	Hold	30,000	–	–	﹤0.01%	367
2024 Q4	$295K	Sell	30,000 -26,750	-47%	-$229K	﹤0.01%	327
2024 Q3	$463K	Sell	56,750 -125,000	-69%	-$1.25M	0.01%	297
2024 Q2	$2.24M	Buy	181,750 +6,750	+4%	+$201K	0.03%	177
2024 Q1	$8.12M	Hold	175,000	–	–	0.11%	105
2023 Q4	$11.8M	Hold	175,000	–	–	0.18%	92
2023 Q3	$12.7M	Buy	+175,000	New	+$14M	0.21%	91

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Welch & Forbes's DNA Position: Q2 2026 in Review

Welch & Forbes held its Ginkgo Bioworks (DNA) position steady in Q2 2026 at 30,000 shares worth $297K. The position accounts for ﹤0.01% of the portfolio, ranked #342.

Welch & Forbes first reported a position in DNA in Q3 2023 and has held it in 12 quarters since. The position peaked at $12.7M in Q3 2023. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Welch & Forbes held 30,000 shares of Ginkgo Bioworks worth $297K as of Q2 2026.
Welch & Forbes left its Ginkgo Bioworks share count unchanged in Q2 2026.
Ginkgo Bioworks made up ﹤0.01% of Welch & Forbes's portfolio in Q2 2026, its #342 holding.
Welch & Forbes first reported a position in Ginkgo Bioworks in Q3 2023 and has held it in 12 quarters since.
Welch & Forbes's Ginkgo Bioworks position peaked at $12.7M in Q3 2023.
184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Welch & Forbes's 13F filing for Q2 2026, filed 30 Jul 2026.